RxDoctor Payments Data

Maureen Muturi

Physician Assistant · Woodland, CANPI 1417549114

Payments from drug & device makers

$4,965in general payments, 2019–2025

Across 258 payments — averaging $19.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$1K
  • Teva Pharmaceuticals USA, Inc.$610
  • Johnson & Johnson$598
  • Alkermes, Inc.$420
  • AbbVie$412
  • Otsuka America Pharmaceutical, Inc.$408
  • plus $1K from 10 others

What the payments were for

  • Food & beverage$4,85198%
  • Education$1152%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,965 in reported general payments places this provider in the 90th percentile of 10,423 physician assistant providers in California.

See all physician assistant providers in California

Medicare billing

Part B allowed, 2024
$16,942
Medicare patients
42
Services billed
148

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate15$155,445
Invega SustennaPaliperidone Palmitate25$60,175
Abilify MaintenaAripiprazole18$47,245
RexultiBrexpiprazole16$40,207
VraylarCariprazine Hcl23$34,661
Aripiprazole85$15,815
AuvelityDextromethorphan Hbr/Bupropion15$14,276
Lurasidone Hcl45$10,252
Paliperidone ErPaliperidone44$8,967
Quetiapine Fumarate104$1,906
Perphenazine33$1,810
Hydroxyzine Hcl78$1,799
Divalproex Sodium17$1,441
Clomipramine Hcl20$1,082
Olanzapine49$821

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$1,104$155,44515 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$408$87,45234 claims
Johnson & JohnsonInvega Sustenna$598$60,17525 claims
AbbVieVraylar$412$34,66123 claims
Almatica Pharma LLCSertraline Hcl$64$22076 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,423 physician assistant providers in California.

Other physician assistant in Woodland

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →